345 related articles for article (PubMed ID: 28640195)
21. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
22. Saving ears and kidneys from cisplatin.
Wensing KU; Ciarimboli G
Anticancer Res; 2013 Oct; 33(10):4183-8. PubMed ID: 24122981
[TBL] [Abstract][Full Text] [Related]
23. Monitoring treatment of acute kidney injury with damage biomarkers.
Pianta TJ; Succar L; Davidson T; Buckley NA; Endre ZH
Toxicol Lett; 2017 Feb; 268():63-70. PubMed ID: 28065798
[TBL] [Abstract][Full Text] [Related]
24. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
Yokoo S; Yonezawa A; Masuda S; Fukatsu A; Katsura T; Inui K
Biochem Pharmacol; 2007 Aug; 74(3):477-87. PubMed ID: 17582384
[TBL] [Abstract][Full Text] [Related]
25. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
26. Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
Selim MS; Kassem AB; El-Bassiouny NA; Salahuddin A; Abu El-Ela RY; Hamza MS
Med Oncol; 2023 Jan; 40(2):80. PubMed ID: 36650399
[TBL] [Abstract][Full Text] [Related]
27. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
[TBL] [Abstract][Full Text] [Related]
28. Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).
Saad AAA; Zhang F; Mohammed EAH; Wu X
Biol Pharm Bull; 2022; 45(4):382-393. PubMed ID: 35370262
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z; Duin NJCB; Jansen K; Vijverberg SJH; Maitland-van der Zee AH; Masereeuw R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927790
[TBL] [Abstract][Full Text] [Related]
30. Effect of lycopene against cisplatin-induced acute renal injury in rats: organic anion and cation transporters evaluation.
Erman F; Tuzcu M; Orhan C; Sahin N; Sahin K
Biol Trace Elem Res; 2014 Apr; 158(1):90-5. PubMed ID: 24531880
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cisplatin-induced injury in human kidney organoids.
Digby JLM; Vanichapol T; Przepiorski A; Davidson AJ; Sander V
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F971-F978. PubMed ID: 32150447
[TBL] [Abstract][Full Text] [Related]
32. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
[TBL] [Abstract][Full Text] [Related]
33. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
34. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
[TBL] [Abstract][Full Text] [Related]
35. Identification of urinary candidate biomarkers of cisplatin-induced nephrotoxicity in patients with carcinoma.
Jiang W; Ma T; Zhang C; Tang X; Xu Q; Meng X; Ma T
J Proteomics; 2020 Jan; 210():103533. PubMed ID: 31629959
[TBL] [Abstract][Full Text] [Related]
36. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
37. [Platinum agent-induced nephrotoxicity via organic cation transport system].
Yonezawa A
Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective mechanisms of chlorogenic acid in cisplatin-induced kidney injury.
Domitrović R; Cvijanović O; Šušnić V; Katalinić N
Toxicology; 2014 Oct; 324():98-107. PubMed ID: 25043994
[TBL] [Abstract][Full Text] [Related]
39. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Franke RM; Kosloske AM; Lancaster CS; Filipski KK; Hu C; Zolk O; Mathijssen RH; Sparreboom A
Clin Cancer Res; 2010 Aug; 16(16):4198-206. PubMed ID: 20601443
[TBL] [Abstract][Full Text] [Related]
40. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.
George B; Wen X; Mercke N; Gomez M; O'Bryant C; Bowles DW; Hu Y; Hogan SL; Joy MS; Aleksunes LM
Clin Pharmacol Ther; 2017 Apr; 101(4):510-518. PubMed ID: 28002630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
